MedTrace Logo

The CHORAL Flow Study

NCT04073134 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-08-06

No results posted yet for this study

Summary

CHORAL Flow is a randomised, double blinded, placebo-controlled trial of the effects of evolocumab on coronary flow at 12 weeks.

Conditions

Interventions

BIOLOGICAL

Evolocumab

Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

DRUG

Placebo

Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Ricardo Petraco, PhD · Imperial College London

  • Henry Seligman, MBBS · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-11
Primary Completion
2022-03-27
Completion
2022-05-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073134 on ClinicalTrials.gov